PROTEIN ENRICHED MICROVESICLES AND METHODS OF MAKING AND USING THE SAME
The present invention relates to a microvesicle comprising: (i) a membrane-associated protein comprising at least one first dimerization domain, (ii) a carrier protein comprising at least one second dimerization domain, and (iii) a solute that binds to the carrier protein, wherein the solute is selected from the group of: DNA, RNA, protein, carbohydrate, ribosomes, mitochondria, and small molecules. Also provided are cells, reagents and kits that find use in making the microvesicles, as well as methods of using the microvesicles, e.g., in research and therapeutic applications
1 . A microvesicle comprising:
(i) a membrane-associated protein comprising at least one first dimerization domain,
(ii) a carrier protein comprising at least one second dimerization domain, and
(iii) a solute that binds to the carrier protein, wherein the solute is selected from the group of: DNA, RNA, protein, carbohydrate, ribosomes, mitochondria, and small molecules.
2 . The microvesicle according to claim 1 , wherein the solute is single guide RNA and the carrier protein is a nuclease.
3 . The microvesicle according to claim 2 , wherein the nuclease is CAS9, CAS9 mutant without nuclease activity, or Nickase mutant of Cas9.
4 . The microvesicle according to claim 3 , wherein the single guide RNA comprises the nucleic acid sequence of SEQ ID NO: 1 or 2, and the nuclease is CAS9.
5 . The microvesicle according to claim 2 , wherein the nuclease is Argonaute nuclease.
6 . The microvesicle according to claim 1 , wherein the solute is RNA and the carrier protein is a RNA binding protein.
7 . The microvesicle according to claim 6 , wherein the RNA binding protein is bacteriophage MS2 coat protein, lambdaN22, PUMILIO1, or SRSF1 deletion mutants.
8 . The microvesicle according to claim 1 , wherein the solute is DNA and the carrier protein is a DNA binding protein.
9 . The microvesicle according to claim 1 , wherein the membrane-associated protein is selected from the group consisting of a myristoylated protein, a farnesylated protein, a membrane anchor protein, a transmembrane protein, and membrane lipid protein.
10 . The microvesicle according to claim 1 , wherein the membrane-associated protein and the carrier protein are bound to each other through the first and the second dimerization domain and form a multimerized complex.
11 . The microvesicle according to claim 10 , wherein first and second dimerization domains are bound to each other by a dimerization mediator.
12 . The microvesicle according to claim 1 , wherein the microvesicle further comprises a microvesicle inducer.
13 . The microvesicle according to claim 12 , wherein the microvesicle inducer is selected from the group consisting of a viral membrane fusion protein, a chemical inducer, proteolipid protein PLP1, the clathrin adaptor complex AP1, floppase, flippase scramblase, TSAP6 and CHMP4C.
14 . The microvesicle according to claim 1 , wherein the first and second dimerization domains are selected from DmrA and DmrC domains, DmrB domains, DmrD domains, dimerization domains of the dihydrofolate reductase system, dimerization domains of TAg and p53, and dimerization domains of SH2 and a PTRK protein.
15 . A method of preparing the microvesicle according to claim 1 , the method comprising:
(a) maintaining a packaging cell comprising:
(i) the membrane-associated protein comprising at least one first dimerization domain,
(ii) the carrier protein comprising at least one second dimerization domain, and
(iii) the solute that binds to the carrier protein, and
(b) producing the microvesicle from the packaging cell under sufficient conditions.
16 . The method according to claim 15 , wherein the packaging cell further comprises:
a first expression cassette comprising a first coding sequence for encoding the membrane-associated protein comprising a first dimerization domain; and
a second expression cassette comprising a second coding sequence for encoding the carrier protein comprising a second dimerization domain.
17 . The method according to claim 16 , wherein the packaging cell further comprises a third expression cassette comprising a third coding sequence for encoding the solute selected from the group of RNA, and protein.
18 . A microvesicle comprising:
(i) a membrane-associated protein comprising at least one first dimerization domain, and
(ii) a nuclease protein comprising at least one second dimerization domain,
wherein said nuclease is selected from the group consisting of a Cas protein, and Argonaute nuclease.
19 . The microvesicle according to claim 18 , wherein the Cas protein is elected from the group consisting of: Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, homologues thereof, and modified versions thereof.
20 . The microvesicle according to claim 18 , wherein the membrane-associated protein and the nuclease are bound to each other through the first and the second dimerization domain and form a multimerized complex.